OCREVUS is a CD20-directed cytolytic antibody indicated for the treatment of Multiple Sclerosis.
• Injection: 300 mg/10 mL (30 mg/mL) in a single-dose.
"• Hepatitis B virus screening is required before the first dose.
• Pre-medicate with methylprednisolone (or an equivalent corticosteroid) and an antihistamine (e.g., diphenhydramine) prior to each infusion.
• Administer OCREVUS by intravenous infusion.
o Start dose: 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion.
o Subsequent doses: 600 mg intravenous infusion every 6 months.
• Must be diluted prior to administration.
• Monitor patients closely during and for at least one hour after infusion"
• Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
• Primary progressive MS, in adults